Outcome measure | Evidence | Implications |
---|---|---|
Disease-oriented evidence | ||
Statistically significant PASI 75 responses | Clear | Ustekinumab effectively controls psoriasis and improves clearance rates compared to placebo |
Time to relapse | Substantial | The median time to loss of PASI 75 after withdrawal was about 15 weeks |
Patient-oriented evidence | ||
Quality of life improvement | Clear | Ustekinumab considerably improves quality of life in psoriatic patients compared to placebo |
Tolerability | Moderate | Safety profile similar to other biologics Further studies are required to evaluate long-term tolerability |
Economic evidence | ||
Cost effectiveness | No evidence |
Abbreviations: PASI, Psoriasis Area and Severity Index.